Pfizer introduces 75 mg orally disintegrating tablet for adults, offering fast and sustained migraine relief
Key Highlights
- Pfizer has launched Rimegepant ODT (75 mg) in India, a major advancement in migraine treatment.
- Rimegepant is a CGRP receptor antagonist, targeting the neuropeptide responsible for migraine pain.
- Clinical studies show relief may last up to 48 hours, and the orally disintegrating tablet dissolves in the mouth without water.
- Suitable for adults whose migraines do not respond to traditional treatments like triptans.
- The launch could significantly improve migraine care in India, where the condition affects millions.
Pfizer has launched Rimegepant in India as a 75 mg orally disintegrating tablet (ODT) for the treatment of migraine in adults. This represents a significant step forward for patients seeking effective migraine relief, especially those who have not benefited from conventional therapies like triptans.
How Rimegepant Works
Rimegepant is a CGRP (calcitonin gene-related peptide) receptor antagonist. CGRP is a neuropeptide that rises during migraine attacks, causing blood vessel dilation and pain signaling. By blocking the CGRP receptor, Rimegepant interrupts this process, providing relief from migraine pain. Unlike triptans, Rimegepant does not constrict blood vessels, making it a safer option for patients with cardiovascular concerns.
Advantages of the ODT Form
- The orally disintegrating tablet dissolves quickly in the mouth, requiring no water.
- A single dose can provide relief for up to 48 hours, reducing the need for frequent medication.
- The extended relief lowers the risk of medication-overuse headaches, a common issue with frequent migraine treatment.
Impact for Patients in India
Rimegepant is intended for the acute treatment of migraines, offering a fast-acting and long-lasting alternative for adults whose symptoms are inadequately managed by other medications. With migraine being a prevalent and often debilitating condition in India, this launch provides new hope for improved productivity, quality of life, and patient well-being.
Impact on Migraine Patients
- Advanced Treatment: Offers an effective alternative for patients not responding to older therapies.
- Convenience: Orally disintegrating form improves compliance and ease of use.
- Sustained Relief: Provides up to 48 hours of migraine pain relief per dose.
- Public Health Impact: Could improve daily life and productivity for millions of Indian migraine sufferers.
Also Read : Harvard-Trained Gastroenterologist Reveals 3 Simple Tips To Reduce Belly Fat Fast
